請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60294
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 丁詩同(Shih-Torng Ding) | |
dc.contributor.author | Ting-Wei Huang | en |
dc.contributor.author | 黃亭維 | zh_TW |
dc.date.accessioned | 2021-06-16T10:14:59Z | - |
dc.date.available | 2023-02-16 | |
dc.date.copyright | 2021-02-22 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-02-08 | |
dc.identifier.citation | Abd El-Kader, S. M., and El-Den Ashmawy, E. M. 2015. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol, 7(6),846-858. Altinbas, A., Sowa, J. P., Hasenberg, T., and Canbay, A. 2015. The diagnosis and treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol, 61(3),159-169. Ampong, I., Watkins, A., Gutierrez-Merino, J., Ikwuobe, J., and Griffiths, H. R. 2020. Dietary protein insufficiency: An important consideration in fatty liver disease? Br J Nutr, 123(6),601-609. Arab, J. P., Arrese, M., and Trauner, M. 2018. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol, 13,321-350. Ayala, I., Castillo, A. M., Adanez, G., Fernandez-Rufete, A., Perez, B. G., and Castells, M. T. 2009. Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis. Exp Biol Med (Maywood), 234(1),10-16. Badaloo, A., Reid, M., Soares, D., Forrester, T., and Jahoor, F. 2005. Relation between liver fat content and the rate of vldl apolipoprotein b-100 synthesis in children with protein-energy malnutrition. Am J Clin Nutr, 81(5),1126-1132. Bortolotti, M., Maiolo, E., Corazza, M., Van Dijke, E., Schneiter, P., Boss, A., Carrel, G., Giusti, V., Le, K. A., Quo Chong, D. G., Buehler, T., Kreis, R., Boesch, C., and Tappy, L. 2011. Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients. Clin Nutr, 30(4),494-498. Baumeier, C., Schlüter, L., Saussenthaler, S., Laeger, T., Rödiger, M., Alaze, S. A., Fritsche, L., Häring, H. U., Stefan, N., Fritsche, A., Schwenk, R. W., and Schürmann, A. 2017. Elevated hepatic dpp4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol Metab, 6(10),1254-1263. Bril, F., Barb, D., Portillo-Sanchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., and Cusi, K. 2017. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology, 65(4),1132-1144. Butler, E. J. 1976. Fatty liver diseases in the domestic fowl--a review. Avian Pathol, 5(1),1-14. Chakravarthy, M. V., Waddell, T., Banerjee, R., and Guess, N. 2020. Nutrition and nonalcoholic fatty liver disease: Current perspectives. Gastroenterol Clin North Am, 49(1),63-94. Choi, H. N., Jang, Y. H., Kim, M. J., Seo, M. J., Kang, B. W., Jeong, Y. K., and Kim, J. I. 2014. Cordyceps militaris alleviates non-alcoholic fatty liver disease in ob/ob mice. Nutr Res Pract, 8(2),172-176. Choi, Y. I., Ahn, H. J., Lee, B. K., Oh, S. T., An, B. K., and Kang, C. W. 2012. Nutritional and hormonal induction of fatty liver syndrome and effects of dietary lipotropic factors in egg-type male chicks. Asian-Australas J Anim Sci, 25(8),1145-1152. Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., Thornberry, N. A., and Zhang, B. B. 2003. Mice lacking dipeptidyl peptidase iv are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A, 100(11),6825-6830. Corbin, K. D., and Zeisel, S. H. 2012. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol, 28(2),159-165. Cornelius, C. E., and Kaneko, J. J. (1963). Clinical biochemistry of domestic animals. New York ( London): Academic Press. Cui, A., Hu, Z., Han, Y., Yang, Y., and Li, Y. 2017. Optimized analysis of in vivo and in vitro hepatic steatosis. J Vis Exp(121). Diaz, G. J., Squires, E. J., and Julian, R. J. 1999. The use of selected plasma enzyme activities for the diagnosis of fatty liver-hemorrhagic syndrome in laying hens. Avian Dis, 43(4),768-773. Dong, X., and Tong, J. 2019. Different susceptibility to fatty liver-haemorrhagic syndrome in young and older layers and the interaction on blood ldl-c levels between oestradiols and high energy-low protein diets. Br Poult Sci, 60(3),265-271. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. J. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest, 115(5),1343-1351. Ejima, C., Kuroda, H., and Ishizaki, S. 2016. A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis. Physiol Rep, 4(21). Estes, C., Razavi, H., Loomba, R., Younossi, Z., and Sanyal, A. J. 2018. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 67(1),123-133. Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., and Sanyal, A. J. 2018. Mechanisms of nafld development and therapeutic strategies. Nat Med, 24(7),908-922. Fujita, K., Nozaki, Y., Wada, K., Yoneda, M., Fujimoto, Y., Fujitake, M., Endo, H., Takahashi, H., Inamori, M., Kobayashi, N., Kirikoshi, H., Kubota, K., Saito, S., and Nakajima, A. 2009. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology, 50(3),772-780. Gao, X., Liu, P., Wu, C., Wang, T., Liu, G., Cao, H., Zhang, C., Hu, G., and Guo, X. 2019. Effects of fatty liver hemorrhagic syndrome on the amp-activated protein kinase signaling pathway in laying hens. Poult Sci, 98(5),2201-2210. Garcia Caraballo, S. C., Comhair, T. M., Dejong, C. H. C., Lamers, W. H., and Koehler, S. E. 2017. Dietary treatment of fatty liver: High dietary protein content has an antisteatotic and antiobesogenic effect in mice. Biochim Biophys Acta Mol Basis Dis, 1863(7),1789-1804. Ghorpade, D. S., Ozcan, L., Zheng, Z., Nicoloro, S. M., Shen, Y., Chen, E., Bluher, M., Czech, M. P., and Tabas, I. 2018. Hepatocyte-secreted dpp4 in obesity promotes adipose inflammation and insulin resistance. Nature, 555(7698),673-677. Gorgens, S. W., Jahn-Hofmann, K., Bangari, D., Cummings, S., Metz-Weidmann, C., Schwahn, U., Wohlfart, P., Schafer, M., and Bielohuby, M. 2019. A sirna mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice. PLoS One, 14(12),e0225835. Griffin, H. D., Guo, K., Windsor, D., and Butterwith, S. C. 1992. Adipose tissue lipogenesis and fat deposition in leaner broiler chickens. J Nutr, 122(2),363-368. Haghighi-Rad, F., and Polin, D. 1981. The relationship of plasma estradiol and progesterone levels to the fatty liver hemorrhagic syndrome in laying hens. Poult Sci, 60(10),2278-2283. Ho, C. M., Ho, S. L., Jeng, Y. M., Lai, Y. S., Chen, Y. H., Lu, S. C., Chen, H. L., Chang, P. Y., Hu, R. H., and Lee, P. H. 2019. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease. J Inflamm (Lond), 16,7. Itou, M., Kawaguchi, T., Taniguchi, E., and Sata, M. 2013. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol, 19(15),2298-2306. Julian, R. J. 2005. Production and growth related disorders and other metabolic diseases of poultry--a review. Vet J, 169(3),350-369. Kabbany, M. N., Conjeevaram Selvakumar, P. K., Watt, K., Lopez, R., Akras, Z., Zein, N., Carey, W., and Alkhouri, N. 2017. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the united states: An analysis of national health and nutrition examination survey data. Am J Gastroenterol, 112(4),581-587. Kawaguchi, T., Nakano, D., Koga, H., and Torimura, T. 2019. Effects of a dpp4 inhibitor on progression of nash-related hcc and the p62/ keap1/nrf2-pentose phosphate pathway in a mouse model. Liver Cancer, 8(5),359-372. Krajcovicová-Kudlácková, M., Simoncic, R., Béderová, A., Babinská, K., and Béder, I. 2000. Correlation of carnitine levels to methionine and lysine intake. Physiol Res, 49(3),399-402. Laliotis, G. P., Bizelis, I., and Rogdakis, E. 2010. Comparative approach of the de novo fatty acid synthesis (lipogenesis) between ruminant and non ruminant mammalian species: From biochemical level to the main regulatory lipogenic genes. Curr Genomics, 11(3),168-183. Lee, B. K., Kim, J. S., Ahn, H. J., Hwang, J. H., Kim, J. M., Lee, H. T., An, B. K., and Kang, C. W. 2010. Changes in hepatic lipid parameters and hepatic messenger ribonucleic acid expression following estradiol administration in laying hens (gallus domesticus). Poult Sci, 89(12),2660-2667. Letexier, D., Pinteur, C., Large, V., Fréring, V., and Beylot, M. 2003. Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue. J Lipid Res, 44(11),2127-2134. Leveille, G. A., O'hea, E. K., and Chakbabarty, K. 1968. In vivo lipogenesis in the domestic chicken. Proc Soc Exp Biol Med, 128(2),398-401. Lin, C.-W., Huang, T.-W., Peng, Y.-J., Lin, Y.-Y., Mersmann, H. J., and Ding, S.-T. 2020. A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets. Poultry Science. Longo, N., Frigeni, M., and Pasquali, M. 2016. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta, 1863(10),2422-2435. Loomba, R., and Sanyal, A. J. 2013. The global nafld epidemic. Nat Rev Gastroenterol Hepatol, 10(11),686-690. Meneses, M. E., Martínez-Carrera, D., Torres, N., Sánchez-Tapia, M., Aguilar-López, M., Morales, P., Sobal, M., Bernabé, T., Escudero, H., Granados-Portillo, O., and Tovar, A. R. 2016. Hypocholesterolemic properties and prebiotic effects of mexican ganoderma lucidum in c57bl/6 mice. PLoS One, 11(7),e0159631. Mete, A., Giannitti, F., Barr, B., Woods, L., and Anderson, M. 2013. Causes of mortality in backyard chickens in northern california: 2007-2011. Avian Dis, 57(2),311-315. Nargis, T., and Chakrabarti, P. 2018. Significance of circulatory dpp4 activity in metabolic diseases. IUBMB Life, 70(2),112-119. Nishina, S., Yamauchi, A., Kawaguchi, T., Kaku, K., Goto, M., Sasaki, K., Hara, Y., Tomiyama, Y., Kuribayashi, F., Torimura, T., and Hino, K. 2019. Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice. Cell Mol Gastroenterol Hepatol, 7(1),115-134. Niu, L., Geyer, P. E., Wewer Albrechtsen, N. J., Gluud, L. L., Santos, A., Doll, S., Treit, P. V., Holst, J. J., Knop, F. K., Vilsboll, T., Junker, A., Sachs, S., Stemmer, K., Muller, T. D., Tschop, M. H., Hofmann, S. M., and Mann, M. 2019. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol, 15(3),e8793. Noureddin, M., Mato, J. M., and Lu, S. C. 2015. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of s-adenosylmethionine. Exp Biol Med (Maywood), 240(6),809-820. Paschos, P., and Paletas, K. 2009. Non alcoholic fatty liver disease two-hit process: Multifactorial character of the second hit. Hippokratia, 13(2): 128. Polyzos, S. A., Kountouras, J., and Mantzoros, C. S. 2017. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol, 42(2),92-108. Puri, P., and Sanyal, A. J. 2012. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup. Clin Liver Dis (Hoboken), 1(4),99-103. Radziejewska, A., Muzsik, A., Milagro, F. I., Martinez, J. A., and Chmurzynska, A. 2020. One-carbon metabolism and nonalcoholic fatty liver disease: The crosstalk between nutrients, microbiota, and genetics. Lifestyle Genom, 13(2),53-63. Rinella, M., and Charlton, M. 2016. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health [Editorial Material]. Hepatology, 64(1),19-22. Rozenboim, I., Mahato, J., Cohen, N. A., and Tirosh, O. 2016. Low protein and high-energy diet: A possible natural cause of fatty liver hemorrhagic syndrome in caged white leghorn laying hens. Poult Sci, 95(3),612-621. Savard, C., Tartaglione, E. V., Kuver, R., Haigh, W. G., Farrell, G. C., Subramanian, S., Chait, A., Yeh, M. M., Quinn, L. S., and Ioannou, G. N. 2013. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology, 57(1),81-92. Savic, D., Hodson, L., Neubauer, S., and Pavlides, M. 2020. The importance of the fatty acid transporter l-carnitine in non-alcoholic fatty liver disease (nafld). Nutrients, 12(8). Shini, A., Shini, S., and Bryden, W. L. 2019. Fatty liver haemorrhagic syndrome occurrence in laying hens: Impact of production system. Avian Pathol, 48(1),25-34. Shini, S., and Bryden, W. L. 2009. Occurrence and control of fatty liver haemorrhagic syndrome (flhs) in caged hens. AECL Project Number, UQ-105. Skovierova, H., Vidomanova, E., Mahmood, S., Sopkova, J., Drgova, A., Cervenova, T., Halasova, E., and Lehotsky, J. 2016. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci, 17(10). Subramanian, S., Goodspeed, L., Wang, S., Kim, J., Zeng, L., Ioannou, G. N., Haigh, W. G., Yeh, M. M., Kowdley, K. V., O'brien, K. D., Pennathur, S., and Chait, A. 2011. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese ldl receptor-deficient mice. J Lipid Res, 52(9),1626-1635. Thomson, A. E., Gentry, P. A., and Squires, E. J. 2003. Comparison of the coagulation profile of fatty liver haemorrhagic syndrome-susceptible laying hens and normal laying hens. Br Poult Sci, 44(4),626-633. Tian, J. Y., Chen, L., Zhang, X. L., Li, J., Han, J., Fu, J. Y., Yang, X. M., Zhang, P. C., and Ye, F. 2013. [investigation of a compound, compatibility of rhodiola crenulata, cordyceps militaris, and rheum palmatum, on metabolic syndrome treatment ii - improving obesity]. Zhongguo Zhong Yao Za Zhi, 38(9),1411-1415. Toshikuni, N., Tsutsumi, M., and Arisawa, T. 2014. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol, 20(26),8393-8406. Trott, C. A., Ruiz Aguila, M. E., and Leaver, A. M. 2014. The clinical significance of immediate symptom responses to manual therapy treatment for neck pain: Observational secondary data analysis of a randomized trial. Man Ther, 19(6),549-554. Trott, K. A., Giannitti, F., Rimoldi, G., Hill, A., Woods, L., Barr, B., Anderson, M., and Mete, A. 2014. Fatty liver hemorrhagic syndrome in the backyard chicken: A retrospective histopathologic case series. Vet Pathol, 51(4),787-795. Tsai, M. T., Chen, Y. J., Chen, C. Y., Tsai, M. H., Han, C. L., Chen, Y. J., Mersmann, H. J., and Ding, S. T. 2017. Identification of potential plasma biomarkers for nonalcoholic fatty liver disease by integrating transcriptomics and proteomics in laying hens. J Nutr, 147(3),293-303. Van Herck, M. A., Vonghia, L., and Francque, S. M. 2017. Animal models of nonalcoholic fatty liver disease-a starter's guide. Nutrients, 9(10). Van Zutphen, T., Ciapaite, J., Bloks, V. W., Ackereley, C., Gerding, A., Jurdzinski, A., De Moraes, R. A., Zhang, L., Wolters, J. C., Bischoff, R., Wanders, R. J., Houten, S. M., Bronte-Tinkew, D., Shatseva, T., Lewis, G. F., Groen, A. K., Reijngoud, D. J., Bakker, B. M., Jonker, J. W., Kim, P. K., and Bandsma, R. H. 2016. Malnutrition-associated liver steatosis and atp depletion is caused by peroxisomal and mitochondrial dysfunction. J Hepatol, 65(6),1198-1208. Varin, E. M., Mulvihill, E. E., Beaudry, J. L., Pujadas, G., Fuchs, S., Tanti, J. F., Fazio, S., Kaur, K., Cao, X., Baggio, L. L., Matthews, D., Campbell, J. E., and Drucker, D. J. 2019. Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic dpp4 inhibition. Cell Metab, 29(2),320-334 e325. Waterlow, J. C. 1975. Amount and rate of disappearance of liver fat in malnourished infants in jamaica. Am J Clin Nutr, 28(11),1330-1336. Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., and Lewis, G. F. 2014. Sitagliptin, a dpp-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes, 63(7),2394-2401. Xu, C., Markova, M., Seebeck, N., Loft, A., Hornemann, S., Gantert, T., Kabisch, S., Herz, K., Loske, J., Ost, M., Coleman, V., Klauschen, F., Rosenthal, A., Lange, V., Machann, J., Klaus, S., Grune, T., Herzig, S., Pivovarova-Ramich, O., and Pfeiffer, A. F. H. 2020. High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and fgf21 levels. Liver Int. Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., and Bugianesi, E. 2018. Global burden of nafld and nash: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 15(1),11-20. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., and Wymer, M. 2016. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1),73-84. Yu, S. H., Chen, S. Y., Li, W. S., Dubey, N. K., Chen, W. H., Chuu, J. J., Leu, S. J., and Deng, W. P. 2015. Hypoglycemic activity through a novel combination of fruiting body and mycelia of cordyceps militaris in high-fat diet-induced type 2 diabetes mellitus mice. J Diabetes Res, 2015,723190. Zang, Y., Samii, S. S., Myers, W. A., Bailey, H. R., Davis, A. N., Grilli, E., and Mcfadden, J. W. 2019. Methyl donor supplementation suppresses the progression of liver lipid accumulation while modifying the plasma triacylglycerol lipidome in periparturient holstein dairy cows. J Dairy Sci, 102(2),1224-1236. Zhang, J. W., Chen, D. W., Yu, B., and Wang, Y. M. 2011. Effect of dietary energy source on deposition and fatty acid synthesis in the liver of the laying hen. Br Poult Sci, 52(6),704-710. Zhang, Y., Liu, Z., Liu, R., Wang, J., Zheng, M., Li, Q., Cui, H., Zhao, G., and Wen, J. 2018. Alteration of hepatic gene expression along with the inherited phenotype of acquired fatty liver in chicken. Genes (Basel), 9(4). Zhong, F., Zhou, X., Xu, J., and Gao, L. 2020. Rodent models of nonalcoholic fatty liver disease. Digestion, 101(5),522-535. Zhu, Y., Mao, H., Peng, G., Zeng, Q., Wei, Q., Ruan, J., and Huang, J. 2021. Effect of jak-stat pathway in regulation of fatty liver hemorrhagic syndrome in chickens. Anim Biosci, 34(1),143-153. Zhuang, Y., Xing, C., Cao, H., Zhang, C., Luo, J., Guo, X., and Hu, G. 2019. Insulin resistance and metabonomics analysis of fatty liver haemorrhagic syndrome in laying hens induced by a high-energy low-protein diet. Sci Rep, 9(1),10141. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60294 | - |
dc.description.abstract | 近年來,隨著肥胖盛行率升高,非酒精性脂肪肝病 (non-alcoholic fatty liver disease, NAFLD) 已是現代常見的慢性肝臟疾病之一。非酒精性脂肪肝病隨著病徵程度輕微從脂肪肝 (simple fatty liver)、非酒精性脂肪肝炎 (non-alcoholic steatohepatitis, NASH)、肝纖維化與硬化 (liver fibrosis and cirrhosis)、嚴重則會發展成肝癌 (hepatocellular carcinoma, HCC)。由於人類和雞隻生合成脂肪的主要器官皆為肝臟,因此本研究擬建立雞隻有效形成脂肪肝模式,以利後續篩選出能防治或改善脂肪肝的機能性成分。 本研究分為三部分,第一部分擬透過不同飼糧配方以快速誘導雞隻發生脂肪肝,實驗將七週齡伊莎蛋雞和蘆花雞各分成四組,分別餵飼以下飼糧配方,依序為控制組 (Control, 17% CP, 5.3% fat, and 1,300 mg/kg choline)、低蛋白高脂肪組 (LPHF, 13% CP, 9.1% fat, and 1,300 mg/kg choline)、高膽固醇低膽鹼組 (CLC, 17% CP, 7.6% fat with additional 2% cholesterol, and 800 mg/kg choline) 及低蛋白高脂肪高膽固醇低膽鹼組 (LPHFCLC, 13% CP, 12.6% fat with additional 2% cholesterol, and 800 mg/kg choline),每隔兩週會測量生長性狀及採血分析生理生化性狀和標記蛋白質濃度,實驗餵飼四週後犧牲採樣。結果發現,蘆花雞和伊莎蛋雞其高膽固醇低膽鹼組以及低蛋白高脂肪高膽固醇低膽鹼組的脂肪肝評分皆較高,組織切片有明顯油滴堆積,肝臟中三酸甘油酯和膽固醇濃度顯著上升,伊莎蛋雞血漿中測量到的生物標記dipeptidyl-peptidase 4 (DPP4) 也明顯升高,證實這兩組飼糧配方在肉雞和蛋雞上皆能夠成功誘導脂肪肝的發生。 第二部分實驗利用前述成功的高膽固醇低膽鹼 (CLC) 模式篩選能防治或改善脂肪肝的機能性成分,進行預防組和治療組實驗,預防組餵飼七週齡伊莎蛋雞CLC飼糧,並分別額外添加0.5%北蟲草、1%北蟲草、0.5%靈芝或1%靈芝,共五組,實驗為期四週犧牲;治療組分為兩部分,第一部分餵飼七週齡伊莎蛋雞CLC飼糧四週以誘導脂肪肝後,再依七週齡血脂濃度隨機分為三組餵飼Control、Control添加0.5%靈芝、Control添加1%靈芝,為期四週後犧牲採樣;治療組第二部分餵飼七週齡伊莎蛋雞CLC飼糧四週以誘導脂肪肝後,依七週齡血脂濃度隨機分為三組餵飼CLC、CLC添加0.5%靈芝、CLC添加1%靈芝,為期四週後犧牲採樣。結果顯示,預防組餵飼CLC以誘導脂肪肝發生的同時,在飼糧中添加0.5%或1%靈芝有降低雞隻脂肪肝的趨勢;治療組第一部分餵飼CLC成功誘發脂肪肝後,改以Control餵飼四週,組織切片中的油滴堆積程度顯著下降,能有效達到治療雞隻脂肪肝的效果;治療組第二部分在飼糧中添加不同濃度靈芝並無明顯抑制脂肪肝之效果。 先前的實驗結果證實透過餵飼四週CLC飼糧後,能成功誘導雞隻發生脂肪肝,而第三部分實驗預期建立快速且誘導脂肪肝程度低於CLC飼糧之模式,以利後續建立可篩選出有效減緩脂肪肝之機能性產物的平台,因此以七週齡伊莎蛋雞餵飼有無添加膽鹼 (+/-)、膽固醇濃度0%、0.5%、1%和2%,進行2x2複因子設計,實驗為期六週,結果顯示,膽固醇與膽鹼之間並無發生交互作用,餵飼1%和2%膽固醇的四組飼糧皆能誘導雞隻形成脂肪肝,而無添加膽鹼之組別,其誘導雞隻形成脂肪肝的程度顯著高於正常添加膽鹼之組別。 綜上所述,為了未來能利用此誘導年輕雞隻形成脂肪肝之模式作為能篩選出更準確的機能性產物以達到預防及治療脂肪肝效果的平台,建議使用正常添加膽鹼之組別,並添加1%膽固醇作為最適當能快速誘導年輕雞隻形成脂肪肝的模式,以利後續可利用在篩選出有助於防治非酒精性脂肪肝的機能性成分。 | zh_TW |
dc.description.abstract | Fatty liver diseases, common metabolic diseases in chickens, can lead to a decrease in egg production and sudden death of chickens. To solve problems caused by the disease, reliable chicken models of fatty liver disease are required. The pathogenesis of fatty liver diseases in chickens is accompanied by an imbalance in lipid homeostasis, such as hepatic lipid accumulation, transportation and metabolism. Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disorder in humans caused by excessive lipid accumulation in livers. According that liver is the primary organ for de novo lipogenesis in chickens and humans, whereas both liver and adipose tissue contribute to de novo lipogenesis in rodents. In this study, we generate rapid chicken models for fatty liver development, seven-week-old ISA female chickens were fed with a control diet (CON, 17% dietary protein, 5.3% fat, and 1300 mg/kg choline), a low protein and high fat diet (LPHF, 13% dietary protein, 9.1% fat, and 1300 mg/kg choline), a high cholesterol with low choline diet (CLC, 17% dietary protein, 7.6% fat with additional 2% cholesterol, and 800 mg/kg choline), a low protein, high fat, high cholesterol and low choline diet (LPHFCLC, 13% dietary protein, 12.6% fat with additional 2% cholesterol, and 800 mg/kg choline) for 4 weeks. Our results showed that the CLC or LPHFCLC diet induced hyperlipidemia. Histological examination and hepatic lipid analysis indicated that the CLC and LPHFCLC diet induced fatty liver steatosis. Plasma dipeptidyl-peptidase 4, a biomarker of fatty liver disease in laying hens, was increased in chickens with the CLC or LPHFCLC diet. Pronounced hepatic ballooning and immune cell infiltration were observed in the steatotic livers in accompany with elevated levels of IL1β and LITAF mRNAs, suggesting that the CLC and LPHFCLC diet also provoked steatohepatitis. These diets also induced hepatic steatosis in Plymouth Rock chickens. Thus, the CLC and LPHFCLC diet can be used to generate a model for fatty liver diseases in different strains of chickens. In ISA chickens fed with CLC diet, hepatic PPARγ, SREBP1c, and FASN mRNA levels were elevated, suggesting that a lipogenesis was enhanced by the CLC treatment. Our results also showed that treatment with a high cholesterol and low choline diet low protein, high fat, high cholesterol and low choline diet for four weeks induced fatty liver disease in chickens. These diets can be utilized to rapidly generate chicken models for fatty liver research. The next step used different concentrations of Cordyceps militaris or Ganoderma lucidum with CLC diet to examined if their effects preventing or ameliorating fatty liver in chickens. The present results showed that 0.5% or 1.0% Ganoderma lucidum supplementation with CLC alleviated fatty liver development by CLC diet in the prevention group. Regardless of Ganoderma lucidum supplementation the induced chicken fatty liver by CLC diet 4 weeks, week alleviated in the curing group. Different concentrations of Ganoderma lucidum failed to ameliorated fatty liver by CLC diet. Previous results confirmed that after four-week feeding with the CLC diets, chickens were successfully induced for fatty liver. So the last part of the experiment is to investigate the interaction dietary of high cholesterol and low choline levels to induce fatty liver. Besides, screening of functional components to prevent or alleviate fatty liver with assessed. Therefore, seven-week-old ISA laying hens were fed with a based diet containing high or low choline (+/-) and different levels of cholesterol (0%, 0.5%, 1% or 2%) in a 2x2 multiple factor design for six weeks. The result showed that the groups of diets fed with 1% and 2% cholesterol induced fatty liver in chickens, while the group with choline supplementation induced severe fatty liver than the normal choline group. Currently, most of the fatty liver models induced by diet in chickens are time consuming. To develop therapeutic methods for prevention of fatty liver diseases, a rapid and reliable chicken model of fatty liver diseases is required. Sum of all, since de novo lipogenesis is primary occurred in the liver both in chickens and human, 1% cholesterol with normal choline group is the best treatment to screen functional ingredients for preventing or ameliorating fatty liver in chickens. These diets can be utilized to rapidly generate chicken models for fatty liver research. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T10:14:59Z (GMT). No. of bitstreams: 1 U0001-0302202121420900.pdf: 18444742 bytes, checksum: f054024c307d720a92c192a3a4d57345 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 中文摘要 i Abstract iii 圖目錄 ix 表目錄 xi 壹、 前言 - 1 - 貳、 文獻探討 - 3 - 一、 脂肪肝疾病 - 3 - (一) 人類肝臟所扮演之角色 - 3 - (二) 非酒精性脂肪肝 (non-alcoholic fatty liver disease, NAFLD) - 3 - (三) 二次打擊學說 - 4 - 二、 經產家禽的脂肪肝疾病 - 5 - (一) 出血性脂肪肝 - 5 - (二) FLHS的發生原因 - 6 - (三) 脂質於肝臟堆積的途徑 - 7 - (四) 飼養環境 - 8 - (五) 飼糧配製 - 8 - (六) 判斷禽體脂肪肝程度的方法 - 9 - 三、 護肝物質 (hepatoprotective ingredients) - 12 - (一) 北蟲草 (Cordyceps militaris) - 12 - (二) 靈芝 (Ganoderma lucidum) - 12 - 參、 材料與方法 - 13 - 一、 動物試驗設計 - 13 - (一) 建立非酒精性脂肪肝模式於蘆花肉母雞 - 13 - (二) 建立非酒精性脂肪肝模式於伊莎褐殼蛋母雞 - 13 - (三) 不同濃度北蟲草及靈芝添加於CLC飼糧以預防雞隻脂肪肝 - 14 - (四) 以CLC誘導雞隻脂肪肝後添加靈芝於日常飼糧以改善脂肪肝 - 14 - (五) 持續以CLC誘導雞隻脂肪肝並添加靈芝於飼糧中以改善脂肪肝 - 14 - (六) 探討膽固醇與膽鹼之交互作用以建立蛋雞非酒精性脂肪肝模式 - 15 - 二、 飼糧配製 - 17 - 三、 生長性狀-體重與採食量之測定 - 21 - 四、 血漿三酸甘油酯、膽固醇、NAFLD生物性指標之測定 - 21 - 五、 肝臟脂肪肝程度評級 - 21 - 六、 肝臟三酸甘油酯與總膽固醇含量之測定 - 21 - 七、 肝臟組織石蠟切片及H E染色 - 22 - 八、 肝臟組織冷凍切片及油紅染色 (oil red O staining) - 22 - 九、 肝臟組織的RNA萃取與相關基因表現量之測定 - 23 - 十、 統計分析 - 24 - 肆、 結果與討論 - 25 - 一、 建立非酒精性脂肪肝模式於伊莎褐殼蛋母雞 - 25 - (一) 伊莎蛋雞試驗間隻日採食量與體重 - 25 - (二) 血漿三酸甘油酯及膽固醇濃度 - 26 - (三) 肝臟外觀脂肪肝程度結果 - 27 - (四) 肝臟組織切片染色結果 - 28 - (五) 肝臟三酸甘油酯及膽固醇含量測定 - 30 - (六) 利用DPP4檢測雞隻血漿中的脂肪肝程度 - 31 - (七) mRNA表現分析 - 32 - (八) 小結 - 35 - 二、 建立非酒精性脂肪肝模式於蘆花肉母雞 - 36 - (一) 蘆花雞試驗間隻日採食量與體重 - 36 - (二) 血漿三酸甘油酯及膽固醇濃度 - 37 - (三) 肝臟外觀脂肪肝程度結果 - 38 - (四) 肝臟組織切片染色結果 - 39 - (五) 肝臟三酸甘油酯及膽固醇含量測定 - 41 - (六) 利用DPP4檢測雞隻血漿中的脂肪肝程度 - 42 - (七) 小結 - 43 - 三、 北蟲草及靈芝添加於CLC飼糧以預防雞隻脂肪肝 - 44 - (一) 預防組試驗間隻日採食量與體重 - 44 - (二) 血漿三酸甘油酯及膽固醇濃度 - 45 - (三) 肝臟外觀脂肪肝程度評級 - 46 - (四) 肝臟組織切片染色結果 - 47 - (五) 肝臟三酸甘油酯及膽固醇含量測定 - 49 - (六) 利用DPP4檢測伊莎蛋雞脂肪肝發展 - 50 - (七) mRNA表現分析 - 51 - (八) 小結 - 53 - 四、 治療組以CLC飼糧誘導脂肪肝後添加靈芝於日常飼糧 - 54 - (一) 治療組試驗間隻日採食量與體重 - 54 - (二) 血漿三酸甘油酯及膽固醇濃度 - 55 - (三) 血漿中DPP4濃度結果 - 56 - (四) 治療組肝臟組織切片染色結果 - 57 - (五) 肝臟三酸甘油酯及膽固醇含量測定 - 58 - (六) 小結 - 59 - 五、 治療組持續以CLC飼糧誘導脂肪肝後添加靈芝 - 60 - (一) 治療組試驗間隻日採食量與體重 - 60 - (二) 血漿三酸甘油酯及膽固醇濃度 - 61 - (三) 治療組肝臟組織切片染色結果 - 63 - (四) 肝臟三酸甘油酯及膽固醇含量測定 - 64 - (五) 血漿中DPP4濃度結果 - 65 - (六) mRNA表現分析 - 66 - (七) 小結 - 69 - 六、 探討膽固醇與膽鹼之交互作用以建立蛋雞NAFL模式 - 70 - (一) 伊莎蛋雞試驗間隻日採食量與體重 - 70 - (二) 血漿三酸甘油酯及膽固醇濃度 - 71 - (三) 肝臟切片染色結果 - 73 - (四) 肝臟三酸甘油酯及膽固醇含量測定 - 76 - (五) 利用DPP4檢測雞隻血漿中的脂肪肝程度 - 77 - (六) mRNA表現分析 - 78 - (七) 小結 - 81 - 伍、 結論 - 82 - 陸、 參考文獻 - 85 - | |
dc.language.iso | zh-TW | |
dc.title | 建立篩選改善非酒精性脂肪肝之機能性成分的雞隻模式 | zh_TW |
dc.title | A Chicken Model for Functional Screening of Ingredients Ameliorating Non-alcoholic Fatty Liver | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林原佑(Yuan-Yu Lin),陳洵一(Shuen-Ei Chen),沈湯龍(Tang-Long Shen) | |
dc.subject.keyword | 雞隻動物模式,非酒精性脂肪肝,膽固醇,膽鹼,機能性成分, | zh_TW |
dc.subject.keyword | chicken model,non-alcoholic fatty liver,functional ingredients,choline,cholesterol, | en |
dc.relation.page | 105 | |
dc.identifier.doi | 10.6342/NTU202100473 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2021-02-12 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
顯示於系所單位: | 動物科學技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0302202121420900.pdf 目前未授權公開取用 | 18.01 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。